ELAVL1通过TL1AmRNA稳定促进胃癌的进展和转移
Tao Jiang1, Sihan Bo2, Yong You2
1Department of Immunology, Basic Medical Institute, Chengde Medical University, Chengde 067000, Hebei, China; Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei, AH, 230000, China.
Experimental cell research
|February 28, 2025
概括
类似ELAV的RNA结合蛋白1 (ELAVL1) 通过稳定TL1AmRNA并激活PI3K/Akt通路来促进胃癌. 准ELAVL1为胃癌提供了一个新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 在RNA生物学,RNA生物学.
背景情况:
- 类似ELAV的RNA结合蛋白1 (ELAVL1) 与瘤进展有关.
- 胃癌 (GC) 仍然是一个重大的全球健康挑战.
- 了解GC的新型调节机制对于开发有效治疗非常重要.
研究的目的:
- 研究ELAVL1在胃癌进展中的作用.
- 为了确定在GC中由ELAVL1调节的特定分子相互作用和途径.
- 探索ELAVL1作为GC的潜在治疗标.
主要方法:
- 使用分子生物学技术研究了ELAVL1和TL1AmRNA的相互作用.
- 评估了ELAVL1过度表达和沉默对GC细胞增殖和迁移的影响.
- 利用裸体小鼠的异种移植瘤模型来评估ELAVL1对瘤生长的影响.
- 在TL1AmRNA上使用RNA识别基因 (RRMs) 确认了ELAVL1结合位.
主要成果:
- ELAVL1在特定区域 (nt 1605-1868和 4324-4587) 直接与TL1AmRNA结合.
- 过度表达ELAVL1增强了GC细胞的增殖和迁移;沉默ELAVL1减少了这些过程.
- 在体内,ELAVL1淘汰会显著抑制异种移植瘤的生长.
- ELAVL1稳定TL1AmRNA,导致PI3K/Akt路径激活和GC进展.
结论:
- ELAVL1通过稳定TL1AmRNA并激活PI3K/Akt通路来促进胃癌的进展.
- 在GC中发现了一种涉及ELAVL1,TL1A mRNA和PI3K/Akt的新型调节轴.
- ELAVL1代表了胃癌治疗的有前途的治疗标.
更多相关视频
12:14CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
Published on: June 2, 2022
3.2K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.4K
相关概念视频
03:18Non-LTR Retrotransposons
11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K